Each of these biotechs are developing a vaccine for the rapidly-spreading coronavirus, and analysts say all 3 have minimum double-digit upside ahead.
Read MorePlus, there are now 8,200 confirmed cases of the Chinese coronavirus, Facebook reported a 51% rise in expenses, and GM said it’s bringing back the Hummer.
Read MoreBuy Target – $3.30 or better Sell Target – TradersPro Sell Signal Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, […]
Read MorePlus, the coronavirus now has more than 6,000 confirmed cases, Apple delivered a blowout quarter, and Boeing said costs related to the grounding of its 737 Max plane have exceeded $18 billion.
Read MorePlus, the Chinese coronavirus has spread to more than 4,600 patients, U.S. consumer confidence grew this month, and the U.K. is allowing vendors to use Huawei hardware in the build-out of the country’s 5G network.
Read MorePlus, Johnson & Johnson’s chief scientific officer said he believes the company can develop a vaccine for the deadly virus within the next couple of months, and GM announced it’s investing $3 billion on the production of electric vehicles.
Read MorePlus, Trump’s impeachment trial gets underway in the Senate today, the World Economic Forum in Davos kicked off, and earnings season marches on with Halliburton reporting.
Read MorePlus, Trump’s Senate impeachment trial formally gets underway today, White House trade advisor Peter Navarro spelled out what the U.S. is looking for in the next round of trade negotiations with China, and Morgan Stanley reported an earnings beat.
Read MorePlus, China and the U.S. are set to sign the “phase one” trade agreement this week, Iran admitted it mistakenly shot down the Ukraine-bound passenger jet, and two aerospace suppliers just agreed to merge.
Read MorePlus, the U.S. just slapped new sanctions on Iran, the Labor Department’s December jobs report disappointed, and Six Flags received two downgrades from the same analyst in less than 24 hours.
Read MoreAnd why he says the stock could see double-digit upside over the next 12 months.
Read MorePlus, initial jobless claims for last week were released, Democrats and Republicans are still in a standoff over the Trump impeachment trial, and Interpol issued an arrest warrant to Lebanon for ousted Nissan chair Ghosn.
Read MorePlus, Tesla began delivering Model 3s from its new Shanghai factory, and AstraZeneca and Merck’s cancer drug just got approved to treat pancreatic cancer.
Read MoreBuy Target – $45.75 Sell Target – TradersPro Sell Signal Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company’s lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and […]
Read MorePlus, the stocks that led the market this decade and the ones analysts are bullish on for the year ahead.
Read More